Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma Orphan Drug Report 2015

 

EvaluateMedTech World Preview 2015, Outlook to 2020

Download EvaluatePharma Orphan Drug Report 2015

With 2020 worldwide sales forecast at $178 billion, the orphan drug market is expected to grow by 11.7% per year, (CAGR 2015 to 2020) nearly doubling the yearly growth of the overall prescription drug market.

Moreover, worldwide orphan drug sales will account for 20.2% of worldwide prescription sales by 2020 (excluding generics) according to the EvaluatePharma Orphan Drug Report 2015.

EvaluatePharma Orphan Drug Report 2015 highlights:

  • Median cost per patient differential is 13.8 times higher for orphan drugs compared to non-orphan
  • Worldwide orphan drug sales forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the overall prescription market growth
  • Celgene overtakes Novartis and climbs to the number one position in orphan drug sales by 2020 thanks to top selling Revlimid
  • Phase III orphan drug development costs half that of non-orphan but Phase III drug development no quicker for orphan than non-orphan
  • Return on investment of Phase III/ filed orphan drugs is 1.14 times greater than the ROI for non-orphan drugs

              EvaluateMedTech World Preview 2015 Infographic

Infographic

Press Release


Download EvaluatePharma Orphan Drug Report 2015